HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Raltitrexed-based chemotherapy for advanced colorectal cancer.

AbstractAIMS:
To evaluate the efficiency and safety profile of raltitrexed-based chemotherapy in the treatment of advanced colorectal cancer.
METHODS:
An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer. The outcomes included overall survival, overall response rate and toxicities.
RESULTS:
This meta-analysis included 11 studies with 4622 patients. Overall, there were no significant differences between the two regimens in terms of overall survival (HR=1.06, 95% CI: 0.96-1.17, P=0.23) or overall response rate (RR=1.09, 95% CI: 0.86-1.38, P=0.47). In subgroup analysis, patients in raltitrexed/oxaliplatin group had significantly higher partial response (RR=1.53, 95% CI: 1.17-2.00, P=0.002), overall response rate (RR=1.42, 95% CI: 1.10-1.82, P=0.006), disease control rate (RR=1.16, 95% CI: 1.04-1.29, P=0.009) and lower progressive disease (RR=0.61, 95% CI: 0.45-0.84, P=0.002) when compared to 5-fluorouracil/leucovorin/oxaliplatin group. Occurrence of severe anemia (RR=2.23, 95% CI: 1.38-3.59, P=0.0001), asthenia (RR=2.29, 95% CI: 1.36-3.84, P=0.002), hepatic disorders (RR=7.51, 95% CI: 1.30-43.56, P=0.02), and nausea/vomit (RR=1.70, 95% CI: 1.03-2.81, P=0.04) were significantly higher with the raltitrexed arm treatment, while frequencies of grade 3/4 alopecia (RR=0.36, 95% CI: 0.26-0.50, P<0.00001) and stomatitis/mucositis (RR=0.14, 95% CI: 0.07-0.31, P<0.00001) were increased in the 5-fluorouracil group.
CONCLUSIONS:
Raltitrexed-based chemotherapy regimen leads to an equivalent overall survival and response rates with acceptable toxicities compared to traditional 5-fluorouracil-based regimen in patients with advanced colorectal cancer. Raltitrexed can be a treatment option for these patients when 5-fluorouracil-based regimens are not tolerated or inappropriate.
AuthorsY Liu, W Wu, W Hong, X Sun, J Wu, Q Huang
JournalClinics and research in hepatology and gastroenterology (Clin Res Hepatol Gastroenterol) Vol. 38 Issue 2 Pg. 219-25 (Apr 2014) ISSN: 2210-741X [Electronic] France
PMID24388340 (Publication Type: Journal Article, Meta-Analysis, Review)
CopyrightCopyright © 2013 Elsevier Masson SAS. All rights reserved.
Chemical References
  • Organoplatinum Compounds
  • Quinazolines
  • Thiophenes
  • Oxaliplatin
  • raltitrexed
  • Leucovorin
  • Fluorouracil
Topics
  • Alopecia (chemically induced)
  • Anemia (chemically induced)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Asthenia (chemically induced)
  • Chemical and Drug Induced Liver Injury
  • Colorectal Neoplasms (drug therapy, pathology)
  • Fluorouracil (administration & dosage, adverse effects)
  • Humans
  • Leucovorin (administration & dosage, adverse effects)
  • Mucositis (chemically induced)
  • Nausea (chemically induced)
  • Organoplatinum Compounds (administration & dosage, adverse effects)
  • Oxaliplatin
  • Quinazolines (administration & dosage, adverse effects)
  • Randomized Controlled Trials as Topic
  • Stomatitis (chemically induced)
  • Thiophenes (administration & dosage, adverse effects)
  • Vomiting (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: